Disruptive Growth & Healthcare Conference Archives - Page 8 of 8

AcelRx Pharmaceuticals (NASDAQ: ACRX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

AcelRx Pharmaceuticals (NASDAQ: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. An NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg) was recently submitted to the FDA for review. The company's follow on product, ZALVISO® (sufentanil sublingual tablet system), designed for the management of moderate-to-severe acute pain in adult patients in the hospital setting, is currently enrolling patients in a phase 3 clinical trial, IAP312. For more information, visit the company's website at www.acelrx.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services…

WednesdayFeb 15, 2017 8:30 am

CombiMatrix Corp. (NASDAQ: CBMX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

CombiMatrix (NASDAQ: CBMX) provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. The company specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix’s testing focuses on advanced technologies, including single nucleotide polymorphism (“SNP”) chromosomal microarray analysis (“CMA”), next generation sequencing (“NGS”), fluorescent in situ hybridization (“FISH”) and high resolution karyotyping. For more information, visit the company’s website at www.combimatrix.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication,…